NDASUBCUTANEOUSINJECTABLE
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
5/8 — Partial
DEPO-SUBQ PROVERA 104 (medroxyprogesterone acetate) by Pfizer is depo-subq provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. First approved in 2004.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEPO-SUBQ PROVERA 104 is a subcutaneous injectable progestin (medroxyprogesterone acetate) approved in 2004 for contraception and endometriosis-related pain. It works by inhibiting gonadotropin secretion to prevent ovulation, thicken cervical mucus, and suppress estradiol, delivering sustained contraceptive and pain-relief effects. The product serves women seeking long-acting reversible or non-oral contraceptive options.
$0.032BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D penetration signals a contracting franchise requiring defensive commercial strategies and rightsizing of field teams.
Mechanism of Action
Depo-subQ provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect. Suppression of serum estradiol concentrations is likely to be responsible for…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Started Dec 2020
60 enrolled
Contraception
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Started Mar 2017
24 enrolled
Contraception
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Started Oct 2016
12 enrolled
PregnancyContraception
Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi
Started Jul 2010
200 enrolled
HIV
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate
Started May 2010
50 enrolled
Fertility
Worked on DEPO-SUBQ PROVERA 104 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.